The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...
The Korean unit of Danish health care giant Novo Nordisk signed a memorandum of understanding with Seoul National University ...
On Jan. 1, North Dakota became the first state in the country where access to drugs like Wegovy is part of the EHB package. About 55,293 of North Dakota's 784,000 residents had coverage through fully ...
Argentina Diabetes Devices Market To Reach US$ 1,031.89 Million By 2033, Growing At A CAGR Of 7.48% Astute Analytica ...
Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback